{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:29:36Z","timestamp":1790443776050,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00259-025-07168-4","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:04:22Z","timestamp":1740175462000},"page":"2906-2917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluating Xerostomia as a side effect of [255Ac]Ac-PSMA therapy in prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-4716","authenticated-orcid":false,"given":"Akram","family":"Al-Ibraheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serin","family":"Moghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Machaba","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Saad","family":"Abdlkadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"7168_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"7168_CR2","first-page":"303","volume-title":"Current therapeutic options in metastatic castration-resistant prostate cancer","author":"G Ingrosso","year":"2018","unstructured":"Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, et al. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol: Elsevier; 2018. pp. 303\u201315."},{"key":"7168_CR3","doi-asserted-by":"publisher","first-page":"796657","DOI":"10.3389\/fonc.2022.796657","volume":"12","author":"J Ma","year":"2022","unstructured":"Ma J, Li L, Liao T, Gong W, Zhang C. Efficacy and safety of (225)Ac-PSMA-617-Targeted alpha therapy in metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis. Front Oncol. 2022;12:796657.","journal-title":"Front Oncol"},{"key":"7168_CR4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/pros.24325","volume":"82","author":"MS Sadaghiani","year":"2022","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Gorin MA, et al. 177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis. Prostate. 2022;82:826\u201335.","journal-title":"Prostate"},{"key":"7168_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2214\/AJR.18.20845","volume":"213","author":"MP Yadav","year":"2019","unstructured":"Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand therapy with (177)Lu-PSMA for metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis. AJR Am J Roentgenol. 2019;213:275\u201385.","journal-title":"AJR Am J Roentgenol"},{"key":"7168_CR6","doi-asserted-by":"crossref","unstructured":"Kratochwil C, Haberkorn U, Giesel FL. 225Ac-PSMA-617 for therapy of prostate cancer. Semin Nucl Med: Elsevier; 2020. pp. 133\u2013\u200940.","DOI":"10.1053\/j.semnuclmed.2020.02.004"},{"key":"7168_CR7","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41391-021-00349-w","volume":"24","author":"S Satapathy","year":"2021","unstructured":"Satapathy S, Sood A, Das CK, Mittal BR. Evolving role of (225)Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021;24:880\u201390.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7168_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00259-021-05434-9","volume":"49","author":"MM Sathekge","year":"2021","unstructured":"Sathekge MM, Bruchertseifer F, Vorster M, Morgenstern A, Lawal IO. Global experience with PSMA-based alpha therapy in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;49:30\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7168_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000531246","volume":"32","author":"GK Parida","year":"2023","unstructured":"Parida GK, Panda RA, Bishnoi K, Agrawal K. Efficacy and safety of Actinium-225 prostate-Specific membrane antigen radioligand therapy in metastatic prostate cancer: A systematic review and metanalysis. Med Princ Pract. 2023;32:178\u201391.","journal-title":"Med Princ Pract"},{"key":"7168_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","volume":"98\u201399","author":"N Heynickx","year":"2021","unstructured":"Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so Far. Nucl Med Biol. 2021;98\u201399:30\u20139.","journal-title":"Nucl Med Biol"},{"key":"7168_CR11","first-page":"45","volume":"11","author":"A Villa","year":"2015","unstructured":"Villa A, Connell CL, Abati S. Diagnosis and management of Xerostomia and hyposalivation. Ther Clin Risk Manag. 2015;11:45\u201351.","journal-title":"Ther Clin Risk Manag"},{"key":"7168_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/hed.10255","volume":"25","author":"JA Logemann","year":"2003","unstructured":"Logemann JA, Pauloski BR, Rademaker AW, Lazarus CL, Mittal B, Gaziano J, et al. Xerostomia: 12-Month changes in saliva production and its relationship to perception and performance of swallow function, oral intake, and diet after chemoradiation. Head Neck. 2003;25:432\u20137.","journal-title":"Head Neck"},{"key":"7168_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0167-8140(02)00025-7","volume":"63","author":"A Maes","year":"2002","unstructured":"Maes A, Huygh I, Weltens C, Vandevelde G, Delaere P, Evers G, Van den Bogaert W. De gustibus: time scale of loss and recovery of tastes caused by radiotherapy. Radiother Oncol. 2002;63:195\u2013201.","journal-title":"Radiother Oncol"},{"key":"7168_CR14","first-page":"9","volume":"13","author":"RC Tatum","year":"1982","unstructured":"Tatum RC, Daniels R. The correlation of radiotherapy to salivary gland reduction and increased caries incidence: a caries control method. Quintessence Int Dent Dig. 1982;13:9\u201311.","journal-title":"Quintessence Int Dent Dig"},{"key":"7168_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s005200100283","volume":"10","author":"L Specht","year":"2002","unstructured":"Specht L. Oral complications in the head and neck radiation patient. Support Care Cancer. 2002;10:36\u20139.","journal-title":"Support Care Cancer"},{"key":"7168_CR16","first-page":"680","volume":"16","author":"ST Sonis","year":"2002","unstructured":"Sonis ST, Fey EG. Oral complications of cancer therapy. Oncol (Williston Park NY). 2002;16:680\u20136. discussion 6, 91.","journal-title":"Oncol (Williston Park NY)"},{"key":"7168_CR17","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1002\/cncr.22302","volume":"107","author":"P Dirix","year":"2006","unstructured":"Dirix P, Nuyts S, Van den Bogaert W. Radiation-induced Xerostomia in patients with head and neck cancer. Cancer. 2006;107:2525\u201334.","journal-title":"Cancer"},{"key":"7168_CR18","unstructured":"Health UDo, Services H. Common terminology criteria for adverse events (CTCAE) v5. 0. Cancer Ther Eval Progr. 2017;155."},{"key":"7168_CR19","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2967\/jnumed.118.214379","volume":"59","author":"T Langbein","year":"2018","unstructured":"Langbein T, Chauss\u00e9 G, Baum RP. Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies. J Nucl Med. 2018;59:1172\u20133.","journal-title":"J Nucl Med"},{"key":"7168_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89.","journal-title":"Syst Rev"},{"key":"7168_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1590\/1516-3180.2017.0277100917","volume":"136","author":"ESN Volpato","year":"2018","unstructured":"Volpato ESN, Betini M, Puga ME, Agarwal A, Cataneo AJM, Oliveira, LDd, et al. Strategies to optimize MEDLINE and EMBASE search strategies for anesthesiology systematic reviews. An experimental study. Sao Paulo Med J. 2018;136:103\u20138.","journal-title":"Sao Paulo Med J"},{"key":"7168_CR22","unstructured":"National Institutes of Health. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, Available online at: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools, 2014. Accessed: July 2024."},{"key":"7168_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"7168_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-11-22","volume":"11","author":"JB Schroll","year":"2011","unstructured":"Schroll JB, Moustgaard R, G\u00f8tzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. BMC Med Res Methodol. 2011;11:1\u20138.","journal-title":"BMC Med Res Methodol"},{"key":"7168_CR25","first-page":"195","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SA. A new improved graphical and quantitative method for detecting bias in meta-analysis. JBI Evid Implement. 2018;16:195\u2013203.","journal-title":"JBI Evid Implement"},{"key":"7168_CR26","first-page":"89","volume":"95","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. A nonparametric trim and fill method of accounting for publication bias in meta-analysis. Am Stat Assoc. 2000;95:89\u201398.","journal-title":"Am Stat Assoc"},{"key":"7168_CR27","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2967\/jnumed.123.265546","volume":"64","author":"N Alan-Selcuk","year":"2023","unstructured":"Alan-Selcuk N, Beydagi G, Demirci E, Ocak M, Celik S, Oven BB, et al. Clinical experience with [(225)Ac]Ac-PSMA treatment in patients with [(177)Lu]Lu-PSMA-Refractory metastatic Castration-Resistant prostate Cancer. J Nucl Med. 2023;64:1574\u201380.","journal-title":"J Nucl Med"},{"key":"7168_CR28","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1007\/s00259-023-06340-y","volume":"50","author":"S Ballal","year":"2023","unstructured":"Ballal S, Yadav MP, Satapathy S, Raju S, Tripathi M, Damle NA, et al. Long-term survival outcomes of salvage [(225)Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study. Eur J Nucl Med Mol Imaging. 2023;50:3777\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7168_CR29","doi-asserted-by":"crossref","unstructured":"Feuerecker B, Gafita A, Langbein T, Tauber R, Seidl C, Bruchertseifer F et al. Comparative analysis of morphological and functional effects of (225)Ac- and (177)Lu-PSMA radioligand therapies (RLTs) on salivary glands. Int J Mol Sci. 2023;24.","DOI":"10.3390\/ijms242316845"},{"key":"7168_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. (225)Ac-PSMA-617\/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7168_CR31","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W et al. Targeted Alpha Therapy of mCRPC with <\u2009sup\u2009>\u2009225\u2009Actinium-PSMA-617: Dosimetry estimate and empirical dose finding. J Nucl Med. 2017:jnumed.117.191395."},{"key":"7168_CR32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795\u2013802.","journal-title":"J Nucl Med"},{"key":"7168_CR33","doi-asserted-by":"crossref","unstructured":"Rathke H, Winter E, Bruchertseifer F, R\u00f6hrich M, Giesel FL, Haberkorn U et al. Deescalated 225Ac-PSMA-617 versus 177Lu\/225Ac-PSMA-617 cocktail therapy: A Single-Center retrospective analysis of 233 patients. J Nucl Med. 2024.","DOI":"10.2967\/jnumed.123.267206"},{"key":"7168_CR34","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.7150\/thno.56211","volume":"11","author":"F Rosar","year":"2021","unstructured":"Rosar F, Hau F, Bartholom\u00e4 M, Maus S, Stemler T, Linxweiler J, et al. Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617\/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy. Theranostics. 2021;11:4050\u201360.","journal-title":"Theranostics"},{"key":"7168_CR35","doi-asserted-by":"crossref","unstructured":"Rosar F, Krause J, Bartholom\u00e4 M, Maus S, Stemler T, Hierlmeier I et al. Efficacy and safety of [(225)Ac]Ac-PSMA-617 augmented [(177)Lu]Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis. Pharmaceutics. 2021;13.","DOI":"10.3390\/pharmaceutics13050722"},{"key":"7168_CR36","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/RLU.0000000000003925","volume":"46","author":"Y Sanli","year":"2021","unstructured":"Sanli Y, Kuyumcu S, Simsek DH, B\u00fcy\u00fckkaya F, Civan C, Isik EG, et al. 225Ac-Prostate-Specific membrane antigen therapy for Castration-Resistant prostate cancer: A Single-Center experience. Clin Nucl Med. 2021;46:943\u201351.","journal-title":"Clin Nucl Med"},{"key":"7168_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","volume":"46","author":"M Sathekge","year":"2019","unstructured":"Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. (225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7168_CR38","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2967\/jnumed.121.263618","volume":"63","author":"M Sathekge","year":"2022","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. mCRPC patients receiving (225)Ac-PSMA-617 therapy in the Post-Androgen deprivation therapy setting: response to treatment and survival analysis. J Nucl Med. 2022;63:1496\u2013502.","journal-title":"J Nucl Med"},{"key":"7168_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2967\/jnumed.119.229229","volume":"61","author":"M Sathekge","year":"2020","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. Predictors of overall and Disease-Free survival in metastatic Castration-Resistant prostate Cancer patients receiving (225)Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61:62\u20139.","journal-title":"J Nucl Med"},{"key":"7168_CR40","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1007\/s00259-023-06165-9","volume":"50","author":"M Sathekge","year":"2023","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Mokoala K, Reed J, et al. (225)Ac-PSMA-617 radioligand therapy of de Novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. Eur J Nucl Med Mol Imaging. 2023;50:2210\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7168_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175\u201383.","journal-title":"Lancet Oncol"},{"key":"7168_CR42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s12149-021-01617-4","volume":"35","author":"I Sen","year":"2021","unstructured":"Sen I, Thakral P, Tiwari P, Pant V, Das SS, Manda D, Raina V. Therapeutic efficacy of (225)Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy. Ann Nucl Med. 2021;35:794\u2013810.","journal-title":"Ann Nucl Med"},{"key":"7168_CR43","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.urolonc.2020.12.002","volume":"39","author":"MJ van der Doelen","year":"2021","unstructured":"van der Doelen MJ, Mehra N, van Oort IM, Looijen-Salamon MG, Janssen MJR, Custers JAE, et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with (225)Ac-PSMA-617 targeted alpha-radiation therapy. Urol Oncol. 2021;39:729. e7-.e16.","journal-title":"Urol Oncol"},{"key":"7168_CR44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.120.251017","volume":"62","author":"MJ Zacherl","year":"2021","unstructured":"Zacherl MJ, Gildehaus FJ, Mittlmeier L, B\u00f6ning G, Gosewisch A, Wenter V, et al. First clinical results for PSMA-Targeted \u03b1-Therapy using (225)Ac-PSMA-I&T in Advanced-mCRPC patients. J Nucl Med. 2021;62:669\u201374.","journal-title":"J Nucl Med"},{"key":"7168_CR45","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.7150\/thno.48107","volume":"10","author":"MP Yadav","year":"2020","unstructured":"Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate Cancer patients. Theranostics. 2020;10:9364\u201377.","journal-title":"Theranostics"},{"key":"7168_CR46","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.3390\/cancers15092592","volume":"15","author":"C Burgard","year":"2023","unstructured":"Burgard C, Rosar F, Marlowe RJ, Bartholom\u00e4 M, Dewes S, Schaefer-Schuler A, et al. Tumor sink effect with prostate-Specific membrane Antigen-Targeted theranostics in patients with metastatic Castration-Resistant prostate cancer: Intra-Individual evaluations. Cancers (Basel). 2023;15:2592.","journal-title":"Cancers (Basel)"},{"key":"7168_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41391-020-0228-0","volume":"24","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, et al. Clinical and genomic characterization of low PSA secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:81\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7168_CR48","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00259-023-06119-1","volume":"50","author":"N Mader","year":"2023","unstructured":"Mader N, Nguyen Ngoc C, Kirkg\u00f6ze B, Baumgarten J, Groener D, Klimek K, et al. Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50:1811\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7168_CR49","doi-asserted-by":"crossref","unstructured":"Al-Ibraheem A, Scott AM. 161\u00a0Tb-PSMA unleashed: a promising new player in the theranostics of prostate cancer. Nucl Med Mol Imaging (2010). 2023;57:168\u2013\u200971.","DOI":"10.1007\/s13139-023-00804-7"},{"key":"7168_CR50","doi-asserted-by":"crossref","unstructured":"Abdlkadir AS, Rosar F, Jalilian A, Moghrabi S, Al-Balooshi B, Rabei O et al. Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review. Nucl Med Mol Imaging (2010). 2024:1\u201312.","DOI":"10.1007\/s13139-024-00891-0"},{"key":"7168_CR51","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2967\/jnumed.122.265291","volume":"64","author":"A Al-Ibraheem","year":"2023","unstructured":"Al-Ibraheem A, Doudeen RM, Juaidi D, Abufara A, Maus S. 161\u00a0Tb-PSMA radioligand therapy: first-in-humans SPECT\/CT imaging. J Nucl Med. 2023;64:1322\u20133.","journal-title":"J Nucl Med"},{"key":"7168_CR52","doi-asserted-by":"crossref","unstructured":"Abdlkadir AS, Abufara A, Al-Ibraheem A. Dual Radionuclide Therapy: The Synergistic Effects of [161\u00a0Tb] Tb-PSMA and [177Lu] Lu-PSMA in Advanced Prostate Cancer Post [177Lu] Lu-PSMA Failure. Nucl Med Mol Imaging (2010). 2024;58:381-2.","DOI":"10.1007\/s13139-024-00871-4"},{"key":"7168_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00259-018-4135-8","volume":"46","author":"H Rathke","year":"2019","unstructured":"Rathke H, Kratochwil C, Hohenberger R, Giesel FL, Bruchertseifer F, Flechsig P, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing (225)Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging. 2019;46:139\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7168_CR54","doi-asserted-by":"publisher","first-page":"531660","DOI":"10.3389\/fonc.2020.531660","volume":"10","author":"ML Belli","year":"2020","unstructured":"Belli ML, Sarnelli A, Mezzenga E, Cesarini F, Caroli P, Di Iorio V, et al. Targeted alpha therapy in mCRPC (Metastatic Castration-Resistant prostate Cancer) patients: predictive dosimetry and toxicity modeling of (225)Ac-PSMA (Prostate-Specific membrane Antigen). Front Oncol. 2020;10:531660.","journal-title":"Front Oncol"},{"key":"7168_CR55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/toxins14010064","volume":"14","author":"J Mueller","year":"2022","unstructured":"Mueller J, Langbein T, Mishra A, Baum RP. Safety of High-Dose botulinum toxin injections for Parotid and submandibular gland radioprotection. Toxins (Basel). 2022;14:64.","journal-title":"Toxins (Basel)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07168-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07168-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07168-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T03:03:22Z","timestamp":1749697402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07168-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7168"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07168-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mike Machaba Sathekge is an editor in this journal. Akram Al-Ibraheem, Serin Moghrabi, and Ahmed Saad Abdlkadir declare that they have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}